Search the Newsreel

Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting

Humacyte has announced that the FDA has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of its coronary tissue engineered vessel (CTEV) for coronary artery bypass grafting (CABG). The company plans to initiate a Phase 2a study in ten adult …

Humacyte Plans First Human Study of Bioengineered Vessel in Heart Bypass

Humacyte (Nasdaq: HUMA) has received FDA acceptance for its Investigational New Drug (IND) application, paving the way for a first-in-human Phase 2a clinical study of its coronary tissue engineered vessel (CTEV) for coronary artery bypass grafting (CABG). The study, expected to enroll ten adult …

PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of PharmaCyte Biotech Inc (PMCB), highlighting major individual and institutional holders. Key shareholders include Joshua Silverman, Citadel Advisors LLC, and HRT Financial LP. The report also breaks down shareholder types and institutional holdings quarter by quarter, showing changes …

Humacyte Says US FDA Accepted IND for Human Trial of Coronary Tissue Engineered Vessel in Surgery

Humacyte, Inc. announced that the US FDA has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of its Coronary Tissue Engineered Vessel (CTEV). This study will evaluate the CTEV for use in Coronary Artery Bypass Grafting (CABG) surgery. The company …

PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for PharmaCyte Biotech Inc (PMCB). It states that the company has not distributed any dividends over the past five years. The page also offers current market data including its stock price, market cap, …

Humacyte Inc (HUMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Macy's Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

This article provides a detailed profile of Macy's Inc (M), an omni-channel retail company operating under the Macy's, Bloomingdale's, and Bluemercury brands. It includes financial data such as market capitalization and P/E ratio, key company information like IPO date and CEO, and a list …

HUMA|Humacyte Inc|Price:0.625|Chg%:-0.014

Humacyte Inc. (HUMA) is a biotechnology company developing universally implantable bioengineered human tissues. The company is in late-stage clinical trials for vascular applications like hemodialysis and peripheral artery disease, and also has preclinical development in other areas. Trading at $0.625, the article provides an …

Macy's Inc (M) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Macy's Inc (M) by business segments. It lists the proportion of revenue contributed by Women's Accessories, Intimate Apparel, Shoes, Cosmetics; Women's Apparel; Men's and Kids; Home/Other; and Other Revenue, based on a reported $9.13 billion for the …

Guardian Pharmacy Services Inc (GRDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey

This article from TradingKey provides a revenue breakdown for Guardian Pharmacy Services Inc (GRDN). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page displays basic stock information including market …

Redcare Pharmacy Aktie: Rx-Geschäft springt 55 Prozent

Macy's Number of Employees 2026 | Employee Count & Headcount Data

Macy's, Inc. (M) had approximately 90,332 total employees worldwide as of March 2026, according to Revelio Labs. This represents a 4.2% decline in headcount from 94,333 employees in 2023. Despite the overall decline, Macy's is actively hiring, with 5,035 active job postings in 2026, …

Price to sales forward of Humacyte, Inc. – NASDAQ:HUMAW

This article from TradingView provides financial information for Humacyte, Inc. (NASDAQ: HUMAW), specifically focusing on its price-to-sales forward metric. The content highlights a specific period, value, and change percentage for this financial indicator, framed within a market data and analysis platform context.

PharmaCyte Biotech, Inc. Revenue Breakdown – NASDAQ:PMCB

This article provides a basic overview of PharmaCyte Biotech, Inc. (NASDAQ: PMCB) on TradingView. It indicates that no trades occurred as the market was closed and highlights the availability of financial data, company information, and community features on the platform for PMCB. The content …

GRDN|Guardian Pharmacy Services Inc|Price:39.400|Chg%:-0.370

Guardian Pharmacy Services Inc. (GRDN) shows strong fundamentals with high revenue and profit growth over the past three years, despite its stock trading sideways recently. Analysts maintain a "Strong Buy" rating with a target price of $47.00, representing a 14.89% upside. However, the company's …

Bessemer Group Inc. Purchases Shares of 78,656 Guardian Pharmacy Services, Inc. $GRDN

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

Humacyte, Inc. (HUMA) saw its stock close at $0.67, a 2.22% increase, outperforming the S&P 500's daily gain, despite a 21.82% drop over the past month. Analysts project a significant increase in EPS and revenue for the upcoming release and the full year, with …

Macy’s, Inc. Names Caitlin Howe Vice President, Investor Relations

Macy's, Inc. has appointed Caitlin Howe as its new Vice President, Investor Relations, effective July 20, 2026. Howe, previously Senior Vice President of Finance at The RealReal, brings extensive experience in investor relations, corporate finance, and M&A from the retail and e-commerce sectors. She …

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Humacyte, Inc. (HUMA) experienced a larger drop than the general market, closing down 1.28% against a backdrop of slight S&P 500 and Nasdaq depreciation, and a 0.59% Dow downswing. The company's stock has fallen 28.09% in the past month, underperforming the Medical sector and …

Is Now The Time To Look At Buying Macy's, Inc. (NYSE:M)?

This article examines whether Macy's, Inc. (NYSE:M) stock presents a good buying opportunity. It likely delves into various financial metrics, market sentiment, and future prospects to assess the investment potential of the retail giant. The analysis will help investors decide if the current market …

PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director SCHECHTER JONATHAN

This document is a Form 4 statement filed by PharmaCyte Biotech, detailing changes in beneficial ownership of securities for Director Jonathan Schechter. The filing indicates transactions related to his holdings within the company.

Guardian Pharmacy Services, Inc. to Report Second Quarter 2026 Financial Results and Host Conference Call

Guardian Pharmacy Services, Inc. (NYSE: GRDN) announced it will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss these results. The company, a leading long-term …

[Form 4/A] PharmaCyte Biotech, Inc. Amended Insider Trading Activity

PharmaCyte Biotech, Inc. Director Michael M. Abecassis filed an amended Form 4/A, which clarifies a previous insider transaction. The amendment states that an earlier reported grant of a stock option was made in error and has since been canceled, resulting in zero shares and …

PharmaCyte Biotech (PMCB) cancels erroneous stock option grant

PharmaCyte Biotech (PMCB) director Robert Weinstein has corrected a stock option award previously granted on March 31, 2026. The initial grant, reported as a Stock Option (Right to Buy), was made in error and has now been officially cancelled. This amendment to the Form …

PharmaCyte Biotech (PMCB) amends Form 4 to cancel option grant

PharmaCyte Biotech director Jonathan Schechter filed an amended insider report (Form 4/A) to cancel a previously reported stock option grant dated March 31, 2026. This amendment clarifies that the initial grant was made in error and has been subsequently cancelled, resulting in zero outstanding …

Starbucks to reopen at Staten Island Mall in October: Here’s a peek at the new layout

A licensed Starbucks cafe is set to reopen at the Staten Island Mall in New Springville, New York, in October. Located inside Macy's women's department on the upper level, this new shop-within-a-shop replaces the previous Starbucks that closed in December. The cafe will be …

Wellness Concepts in Grottoes acquired by Guardian Pharmacy Services

Guardian Pharmacy Services has acquired Wellness Concepts, a long-term care pharmacy based in Grottoes, Virginia. The acquisition means Wellness Concepts will retain its current leadership and staff, including President Brent Atwell, a second-generation pharmacist. This move strengthens Guardian Pharmacy Services' presence in Virginia and …

Guardian Pharmacy to report Q2 2026 results on August 6

Guardian Pharmacy Services will announce its second quarter 2026 financial results after market close on August 6, 2026, followed by a conference call at 4:30 p.m. Eastern Time. The company, which operates 61 licensed pharmacies serving approximately 207,000 residents, will host the call for …

Macy’s Inc. Taps Alex Choueiri as CEO of Bluemercury

Macy's Inc. has appointed Alex Choueiri, a former Kering Beauté executive, as the new CEO of Bluemercury, effective August 3rd. Choueiri brings over 25 years of experience in luxury beauty, having worked at Kering Beauté Americas and L’Oréal. This strategic move aims to leverage …

Macy’s Inc. taps Kering Beauté exec to lead Bluemercury

Macy’s Inc. has appointed Alexandre Choueiri, formerly of Kering Beauté, as the new CEO of Bluemercury, effective August 3. Choueiri brings over 25 years of experience in luxury beauty, having previously led Kering Beauté's Americas region and held various roles at L'Oréal. His appointment …

Warum die Redcare Pharmacy (XTRA:RDC) nach der Anhebung der Prognose für 2026 und dem Wechsel in den SDAX um 11,2 % zulegt

Redcare Pharmacy: +25 Prozent in zwei Tagen – wichtige Marke jetzt geknackt

Redcare hebt 2026-Prognose an: Umsatz 15–17% und bessere Margen lassen Aktie über 60 Euro springen

Redcare Pharmacy-Aktie springt zweistellig an: Online-Apotheke hebt Jahresprognose an

Redcare Pharmacy: Jetzt platzt der Knoten – Prognose pulverisiert Erwartungen

EQS-News: Redcare Pharmacy beschleunigt das Wachstum, steigert die Profitabilität und erhöht die Prognose für das Geschäftsjahr 2026. - boerse.de